Could circRNA be a new biomarker for pre-eclampsia? by Shafabakhsh, R. et al.
Mol Reprod Dev. 2019;86:1773–1780. wileyonlinelibrary.com/journal/mrd © 2019 Wiley Periodicals, Inc. | 1773
Received: 31 May 2019 | Accepted: 22 August 2019
DOI: 10.1002/mrd.23262
R EV I EW ART I C L E
Could circRNA be a new biomarker for pre‐eclampsia?
Rana Shafabakhsh1 | Naghmeh Mirhosseini2 | Shala Chaichian3,4 | Bahram Moazzami4 |
Zahra Mahdizadeh5 | Zatollah Asemi1
1Research Center for Biochemistry and
Nutrition in Metabolic Diseases, Kashan
University of Medical Sciences, Kashan, Iran
2School of Public Health, University of
Saskatchewan, Saskatoon, Saskatchewan,
Canada
3Minimally Invasive Techniques Research
Center in Women, Tehran Medical Sciences
Branch, Islamic Azad University, Tehran, Iran
4Pars Advanced and Minimally Invasive
Medical Manners Research Center, Pars
Hospital, Iran University of Medical Sciences,
Tehran, Iran
5Firoozabadi Clinical Research Development
Unit, Iran University of Medical Sciences,
Tehran, Iran
Correspondence
Zatollah Asemi, Research Center for
Biochemistry and Nutrition in Metabolic
Diseases, Kashan University of Medical
Sciences, Kashan, PO Box: 81151‐87159, Iran.
Email: asemi_r@yahoo.com
Shala Chaichian, Minimally Invasive
Techniques Research Center in Women,
Tehran Medical Sciences Branch, Islamic Azad
University, Tehran, Iran.
Email: shchaichian@gmail.com
Abstract
Pre‐eclampsia is a devastating complication of pregnancy which is characterized by
hypertension and proteinuria in pregnant women. Pre‐eclampsia is important as it is
the leading cause of death. Moreover, untreated pre‐eclampsia might lead to other
lethal complications, for both fetus and mother. Pre‐eclampsia can also affect the
quality of life in affected women. Despite a large number of risk factors for pre‐
eclampsia, these risk factors are able to detect just 30% of women who are
susceptible to pre‐eclampsia. Heterogeneous manifestations of pre‐eclampsia
necessitate the discovery of potential biomarkers required for its early detection.
Circular RNAs (circRNAs) are a type of RNA which are more abundant, specific, and
highly organized compared with other types of RNA. Accordingly, circRNAs have
been suggested as one of the potential biomarkers for different diseases. Recently,
researchers have shown interest in the effects of circRNAs in pre‐eclampsia, although
the current evidence is limited. The majority of obstetricians are probably not aware
of circRNAs as a useful biomarker. Here, we aimed to summarize recent supporting
evidence and assess the mechanisms by which circRNAs are involved in pre‐
eclampsia.
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1 | INTRODUCTION
Pre‐eclampsia is a pregnancy complication which affects about 3–5%
of pregnancies. It is characterized by the occurrence of hypertension
and proteinuria in pregnant women (Mol et al., 2016). Hypertension
in pre‐eclampsia is defined as systolic blood pressure ≥140mmHg
and diastolic blood pressure ≥90mmHg occurred after 20 weeks of
gestation (Damian, Njau, Lisasi, Msuya, & Boulle, 2019). This disease
leads to 70,000–80,000 maternal and 500,000 perinatal mortality
per year worldwide (Hutcheon, Lisonkova, & Joseph, 2011). This
pregnancy‐related syndrome is a major cause of neonatal, fetal, and
maternal death (Saleem et al., 2014). Untreated pre‐eclampsia might
have other lethal consequences, including stroke, renal failure, liver
rupture, and pulmonary edema as well as fetal growth retardation
and preterm birth (Souza et al., 2013). Preterm birth caused by pre‐
eclampsia may result in bronchopulmonary dysplasia in children
(Hansen, Barnés, Folkman, & McElrath, 2010). In addition, pre‐
eclampsia increases the risk of postpartum depression and reduces
the quality of life in women (Blom et al., 2010; Prick et al., 2015). In
developing countries, pre‐eclampsia is the leading cause of maternal
mortality, while in developed countries, enhanced diagnostic meth-
ods and earlier detection make pre‐eclampsia less devastating (Ngoc
et al., 2006).
There is no approved preventive method for pre‐eclampsia,
though screening and early detection of high‐risk women may
improve its management. The major screening is the assessment of
clinical risk factors, including age, body mass index (BMI) and family
history, especially in the first half of the pregnancy (Hyde &
Thornton, 2013). Delivery is the only treatment that is thought to
be effective for this disorder. Identifying the exact cause of pre‐
eclampsia is likely to result in a significant decrease in maternal and
perinatal morbidity and mortality. However, since its etiology
remains unknown, acting effectively for preventing its development
(primary prevention) is not possible. Several factors such as genetic
changes have been suggested to play a key role in the pathogenesis
of pre‐eclampsia. Several gene variants which are involved in some
metabolic processes such as inflammation, thrombophilia, rennin–an-
giothensin system, and oxidative stress have been associated with
pre‐eclampsia (Jebbink et al., 2012; Rana, Karumanchi, & Lindheimer,
2014). The common symptoms of pre‐eclampsia include headache,
epigastric pain, visual impairments, nausea, and vomiting as well as
some neurological, hepatic, renal, and cardiovascular complications
such as the ischemic neurological deficit, liver dysfunction, acute
renal disease, myocardial ischemia, and pulmonary edema. Moreover,
severe pre‐eclampsia may lead to fetal complications, including
growth retardation, neonatal death, stillbirth, and prematurity
(Mol et al., 2016).
Pre‐eclampsia risk factors include history of pre‐eclampsia in
previous pregnancy, chronic kidney diseases, high blood pressure,
diabetes, autoimmune disorders such as systematic lupus erythro-
matosus, first pre‐eclampsia, age over 40 years, pregnancy interval of
more than 10 years, BMI >35 kg/m2, polycystic ovarian syndrome,
and multiple gestation (National Collaborating Center for Women’s
and Children’s Health, 2010). However, these risk factors are able to
detect just 30% of women who are prone to pre‐eclampsia (Saleem
et al., 2014). Due to heterogeneous manifestations of pre‐eclampsia,
potential biomarkers are required for its early detection.
Current evidence shows the relationship between noncoding
RNAs (ncRNAs) and pre‐eclampsia (Ji et al., 2013). One of the well‐
known types of ncRNAs is long noncoding RNAs (lncRNAs), which
consist of more than 200 nucleotides. LncRNAs have many biological
functions including DNA methylation, imprinting regulation, apopto-
sis, cell‐cycle regulation, and angiogenesis (Wilusz, Sunwoo, &
Spector, 2009). Genome‐wide lncRNAs expression patterns indicate
numerous lncRNAs extensively expressed in pre‐eclampsia. Previous
studies have reported that different expression of lncRNAs in pre‐
eclampsia is related to multiple pathways, including trophoblast
invasion (Long et al., 2016), autophagy (Gao et al., 2011, 2012),
apoptosis (Song et al., 2017; Xu et al., 2018; Zou & Sun, 2015),
proliferation (Cao et al., 2017; Li et al., 2018; Xu et al., 2017),
migration, and angiogenesis (Chen et al., 2015; Yu et al., 2018; Zhang
et al., 2015). Circular RNAs (circRNAs), as one type of ncRNAs, have
been demonstrated to function as a potential regulator of other
RNAs transcription like microRNAs (miRNAs). MiRNAs affect almost
all cellular processes from developmental pathways to oncogenesis.
Indeed, miRNAs are able to regulate the expression of the majority of
human proteins (Bartel, 2004). Thus, circRNAs can be involved in a
wide range of pathways in the body through regulating miRNA
expression. CircRNAs as one type of ncRNAs function as a potential
regulator of other RNAs transcription like miRNAs. CircRNAs are
single‐stranded RNAs which are produced via different posttran-
scriptional processes and then become circular (Ojha, Nandani,
Chatterjee, & Prajapati, 2018). Previously, circRNAs were believed to
be produced by errors in alternative splicing and were considered as
genetic accidents (Cocquerelle, Mascrez, Hétuin, & Bailleul, 1993).
Recently, by advancement in RNA sequencing and bioinformatics
methods, potential biological activities of circRNAs have been
approved (Danan, Schwartz, Edelheit, & Sorek, 2012). circRNAs have
a regulatory role in gene expression as well as a pivotal role in
biological development mechanisms, including regulating miRNA
expression, endogenous RNAs, and act as a biomarker in the
diagnosis of different diseases (Liu, Pan, Mao, Liu, & Chen, 2019).
For instance, a large number of circRNAs have been shown to be
involved in many normal processes including development of
embryos, and sperm as well as pathological conditions like
myocardial infarction, Alzheimer’s disease, diabetes, and carcinomas
such as ovarian, breast, and endometrial tumors (Greene et al., 2017;
Liu et al., 2019; Szabo et al., 2015; Vausort et al., 2016; Zheng et al.,
2016).
CircRNAs do not have 3′ and 5′ ends and are protected against
RNA exonucleases. This unique structure has produced a highly stable
marker in nature. CircRNAs have many miRNA binding sites which
help them to act as a miRNA sponge leading to a reduction in the
inhibitory effect of miRNAs on target genes and thereby enhancing the
expression of these genes (Memczak et al., 2013). CircRNAs are more
abundant, more specific, and highly organized compared with other
RNAs. Accordingly, researchers have suggested that circRNAs could
be strong biomarkers for different diseases; however, the exact
mechanisms of circRNAs function are not clear. Recent evidence has
indicated that these molecules may play important roles in various
diseases from cardiovascular and neurological disorders to multiple
neoplasms (Qu et al., 2015). Recently, researchers have shown interest
in the role of circRNAs in pre‐eclampsia and several studies have been
conducted herein. However, most obstetricians are probably not
aware of circRNAs. Here, we aimed to summarize recent supporting
evidence and evaluate the mechanisms by which circRNAs are
involved in pre‐eclampsia.
2 | CircRNAs BIOGENESIS
During the alternative splicing process, some sequences which are
named noncoding introns, are removed from pre‐mRNA to form the
mature linear RNA (Wang et al., 2008). CircRNAs are produced
during a noncanonical form of alternative splicing, although its
detailed mechanism has not been understood yet. Based on recent
findings, back splicing could be the possible mechanism for
circularization of RNA (Liu et al., 2017). Back splicing leads to the
formation of exonic circRNAs (EcircRNAs), circular intronic RNAs
(ciRNAs), and exon–intron circRNAs (EIcircRNAs; Li et al., 2015;
Zhang et al., 2013). CircRNA is produced by special alternative
splicing through exon circularization and intron circularization. There
are two models for circRNA formation via exon circularization,
including intron‐pairing‐driven circularization and lariat‐driven cir-
cularization (Jeck et al., 2013). In the lariat‐driven circularization, a
covalent splice is formed from the 3′ end of the splice donor to the 5′
end of the splice recipient, resulting in a lariat structure which then is
circularized to form an exonic circle. The intron‐pairing‐driven
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depends on the pairing of complementary motifs existing in the
transcriptome (Ye, Chen, Liu, Zhu, & Fan, 2015).
The formation process of intronic circRNA is completely different
from EcircRNA. GU‐rich sequences near the 5′ splice site and the
C‐rich sequences adjacent to the branch point bind together to form a
circle structure followed by the function of spliceosome which cuts out
the intronic and exonic sequences. Recent investigations have indicated
that back splicing is regulated by splicing factors and cis‐elements (Wang
& Wang, 2015). Eventually, introns bind together to produce ciRNAs
(Talhouarne & Gall, 2014). Extracellular vesicles transport circRNAs same
as ncRNAs to the extracellular space. Moreover, other cells take up
extracellular vesicles showing that circRNAs enhance cell–cell commu-
nication (Lasda & Parker, 2016). By the progression of gestation in each
pregnancy, the levels of extracellular vesicles increase in the maternal
plasma (Adam et al., 2017). These extracellular vesicles contain several
proteins, including messenger RNAs (mRNAs) and miRNAs which have
various biological functions and some of them are involved in pre‐
eclampsia (Salomon, Yee, Mitchell, & Rice, 2014). Recently, the role of
circRNAs and extracellular vesicles in the pathogenesis of pre‐eclampsia
has been attractive for researchers (Figure 1).
3 | THE PATHOPHYSIOLOGY OF
PRE‐ECLAMPSIA
There are many investigations in terms of the pathophysiology of
pre‐eclampsia, though the certain mechanisms remain unclear. The
pathophysiology of pre‐eclampsia seems to be multifactorial and
heterogeneous. The common feature of pre‐eclampsia is abnormal
placentation. Normally, during pregnancy the villous cytotropho-
blasts occupy the inner layer of the myometrium, while maternal
spiral arteries lose their endothelium and muscle fibers with
subsequent conversion into low resistance vessels. The invasion of
cytotrophoblast cells into the maternal spiral arteries is not similar in
pre‐eclampsia. Currently, there are three theories for the etiology of
pre‐eclampsia; one theory emphasizes the role of ischemia‐reperfu-
sion which leads to oxidative stress and vascular disorders.
Hypoperfusion of the fetoplacental unit with subsequent hypoxia
leads to increased production of oxygen species and inflammatory
cytokines by the placenta resulting in inflammation and endothelial
dysfunction as well as the expression of clinical features of the
disease, especially in the third trimester.
F IGURE 1 CircRNA formation. CircRNA, circular RNA; ciRNA, circular intronic RNA; EcircRNA, exonic circRNA; EIcircRNA, exon–intron
circRNA; mRNA, messenger RNA [Color figure can beviewed at wileyonlinelibrary.com]
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Endothelial dysfunction is the most frequent pathological feature
of pre‐eclampsia presents as increased endothelial cell permeability
and aggregation of platelet (Wang, Gu, Zhang, & Lewis, 2004).
Endothelial dysfunction lowers the production and activation of
prostaglandins and nitric oxide which are the two famous vasodila-
tors. Subsequently, decreased production of vasodilators (prosta-
glandins and nitric oxide) may enhance the activation of platelets on
the inner lining of spiral arteries. Endothelial dysfunction and platelet
aggregation may lead to increased production of thrombin and fibrin
especially in utero–placental circulation (Redman, 1990). On the
other hand, the suppression of nitric oxide synthesis in the mother
leads to the prevention of embryo implantation (Durán‐Reyes et al.,
1999). Additionally, disruption of endothelial integrity impairs
sodium volume homeostasis and consequently many cardiovascular
parameters such as elevated cardiac output and intravascular
volume. Moreover, alterations in circulating angiogenic and anti-
angiogenic factors have been reported including increased levels of
soluble endoglin and soluble fms‐likely tyrosine kinase‐1 as anti-
angiogenic factors, besides reduced levels of vascular endothelial
growth factor (VEGF) and placental growth factor (PIGF) as
proangiogenic factors (Nilsson, Salonen Ros, Cnattingius, & Lichten-
stein, 2004).
The second theory is immune system alterations. Although
immune system changes are associated with the origin of pre‐
eclampsia, other factors, including proinflammatory cytokines,
neutrophil activation, and endothelial dysfunction, are also related
to the pathophysiology of this syndrome. Increased generation of
immune cells leads to the production of tumor necrosis factor‐α
(TNF‐α) which stimulates apoptosis in the extravillous cytotropho-
blasts (Genbacev, DiFederico, McMaster, & Fisher, 1999). Further-
more, the human leukocyte antigen (HLA) is involved in the invasion
of the spiral arteries. In normal gestation, these cells interact with the
trophoblast due to the production of VEGF and PIGF by natural‐killer
cells. In pre‐eclampsia, these factors are elevated while other HLAs
such as HLA‐G and HLA‐E have been reduced (Colbern, Chiang, &
Main, 1994). Moreover, recent evidence has demonstrated that heme
oxygenase‐1 and its metabolite, carbon monoxide, have a protective
role in pregnancy which are identified as appropriate targets for the
treatment of pre‐eclampsia (Ahmed, 2011). Furthermore, immunol-
ogists believe that pre‐eclampsia is a maternal–fetal immune
maladaptation. Fetal or maternal immune maladaptation leads to
the induction of apoptosis as well as increasing of various cytokines
such as interleukin‐2 (IL‐2), interferon‐γ (IFN‐γ), TNF‐α, and FAS
ligand which are famous mediators of apoptosis (Mor, Straszewski, &
Kamsteeg, 2002).
In the pathogenesis of pre‐eclampsia, increased placental
apoptotic debris may play an important role through deteriorating
inflammatory and immune responses. Also, syncytiotrophoblast
microparticles can attract monocytes and neutrophiles which lead
to increased levels of TNF, IL‐12, and superoxide radicals (Aly et al.,
2004; Sacks, Redman, & Sargent, 2003). In addition, increased
apoptosis leads to the activation of macrophages (Mor et al., 2002).
IL‐12 which is derived from macrophages or monocytes has the main
role in promoting T‐helper‐1 reactions during pre‐eclampsia. IL‐12
can significantly stimulate IFN‐γ production from natural‐killer cells
and naive T cells. Interestingly, IFN‐γ induces monocytes to more
release of IL‐12 which leads to rapid decadence in severe pre‐
eclampsia (Sacks et al., 2003). Taken together, maternal–fetal
immune maladaptation may increase the risk of pre‐eclampsia by
triggering a systematic inflammatory response in mothers. The third
theory is the genetic theory which suggests multiple susceptible
genes which might affect cardiovascular and hemostatic systems and
inflammation. These genes including HLA‐G, the angiotensin‐con-
verting enzyme (I/D) and Type 1 angiotensin II receptor (AGTR1
A1166C) are also associated with several other genes such as
angiotensinogen and endothelial nitric oxide synthase (Mütze,
Rudnik‐Schoneborn, Zerres, & Rath, 2008; Nilsson et al., 2004).
Polymorphism in some genes such as inflammatory regulators leads
to altered transcription of cytokines or some antiangiogenic agents
(Story & Chappell, 2017). Altogether, pre‐eclampsia is a multifactorial
disease in which a wide range of factors are involved from genetics to
inflammatory and immune responses.
4 | CircRNAs AND PRE‐ECLAMPSIA:
LATEST EVIDENCE
Zhang, Yang, Long, & Li (2016) investigated the expression of
circRNAs in the blood of 82 pregnant women who were between 8
and 20 gestation weeks with the aim of identifying the role of
circRNAs in early diagnosis of pre‐eclampsia. Pre‐eclampsia was
detected in 41 subjects while other 41 individuals had a healthy
pregnancy. Human circRNA microarray was used to analyze the
samples. In addition to circRNA, protein factor endoglin concentra-
tion was also measured. The results showed that the blood
concentration of circ_101222 in patients with pre‐eclampsia was
remarkably greater than healthy pregnant women. Circ_101222 in
combination with endoglin had the sensitivity of 0.7073 and the
specificity of 0.8049 for prediction of pre‐eclampsia. This study
introduced a novel method for prediction of pre‐eclampsia, using a
specific circRNA and a protein factor.
Another recent study was conducted with the same purpose using
the placental tissues of pregnant women with pre‐eclampsia (Qian et al.,
2016). The results of microarray analysis detected three circRNAs
which were highly upregulated in pre‐eclampsia, including hsa_circR-
NA_100782, hsa_circRNA_102682, and hsa_circRNA_104820. This
study suggested that circRNAs might take part in the pathogenesis of
pre‐eclampsia through activating miRNA sponges (Qian et al., 2016).
Indeed, identified circRNAs have several binding sites for miRNA‐17
suggesting that these circRNAs are able to regulate the expression of
miRNA‐17 in human placental tissues. miRNA‐17 has been introduced
as an angiogenesis‐related miRNA, which is expressed highly in pre‐
eclampsia (Wang et al., 2012). A previous study indicated that increased
expression of miRNA‐17 in the placenta enhanced developing pre‐
eclampsia through contributing to trophoblast invasion (Chen & Wang,
2013). Thus, differential expression of circRNAs in the placenta may
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lead to upregulation of miRNA‐17 via activating miRNA sponge method,
thereby enhancing the pathogenesis of pre‐eclampsia (Qian et al., 2016).
Bai et al. (2018) investigated the profile of circRNAs in placental tissues
of pre‐eclampsic women, also examined the potential effects of
circRNAs dysregulation on the progression of pre‐eclampsia. They
identified 300 circRNAs differently expressed between women with
pre‐eclampsia and healthy pregnant women. The results of real‐time
quantitative polymerase chain reaction showed that in all patients with
pre‐eclampsia, hg38_circ_0014736 and hsa_circ_0015382 were highly
upregulated and hsa_circ_0007121 was downregulated. Data revealed
that these three circRNAs are significantly associated with the
regulation of transcription, proliferation, response to hypoxia, and
protein binding. This study introduced hsa_circ_0007121 as the circRNA
which was expressed differently between pre‐eclampsia and normal
pregnancy before 20 gestation weeks. So, hsa_circ_0007121 could be an
appropriate noninvasive biomarker for the prediction of pre‐eclampsia.
In another analysis, Zhou et al. (2018) found that 49 circRNAs
differently expressed in placental tissues of women with pre‐eclampsia,
compared to healthy pregnant women. Two of them were upregulated
and others downregulated in pre‐eclampsic cases. These three circRNAs,
including circRNA_3286, circRNA_5593, and circRNA_3800, participated
in several cellular functions in pre‐eclampsia through activating miRNA
sponge (Zhou et al., 2018). In the latest related investigation, the
expression of several mRNAs, ncRNAs, and circRNAs was profiled in
women with pre‐eclampsia and healthy pregnant women to determine a
potential prediction marker for pre‐eclampsia. Among all of the detected
markers, hsa_circ_0036877 was observed to be a potent blood biomarker
for pre‐eclampsia (Hu et al., 2018). Recently, a bioinformatic analysis
reported hsa_circ_0004904 and hsa_circ_0001855 as the two biomarkers
involved in the pathogenesis of pre‐eclampsia, through activating miRNA
sponges which directly target pregnancy‐associated plasma protein‐A
(PAPP‐A). According to previous evidence, low levels of PAPP‐A have
been documented in the serum of pre‐eclampsic women (Jiang et al.,
2018). There are evidence demonstrating the existence of PAPP‐A in the
serum of pre‐eclampsic women (Jiang et al., 2018). Taken together, the
above data indicates that circRNAs are differently expressed in pre‐
eclampsia which provides new insight into the novel biomarkers for the
prediction of pre‐eclampsia. Currently, the exact reason why circRNAs
levels change during pre‐eclampsia is not completely understood. One of
the main functions of circRNAs is the activation of miRNA sponge which
is involved in the pathogenesis of several diseases. On the other hand,
some studies have suggested that circRNAs might play an important role
in the pathogenesis of pre‐eclampsia through activating miRNA sponge
method (Jiang et al., 2018; Qian et al., 2016; Zhou et al., 2018). Thus, we
hypothesize that alterations in the levels of circRNAs may be involved in
the pathogenesis of pre‐eclampsia and associated with its incidence.
However, further investigations are required to evaluate possible
pathways in pre‐eclampsia related to circRNAs (Table 1; Figure 2).
5 | CONCLUSIONS
Pre‐eclampsia is a serious complication of pregnancy which is one of
the main causes of neonatal, fetal, and maternal death. Untreated
pre‐eclampsia can develop many other lethal complications such as
fetal growth retardation and preterm birth. However, several risk
factors have been determined for this disease, which might help with
its diagnosis
Still, its early diagnosis and prediction is the main issue for
obstetricians. In recent years, circRNAs have attracted more
attention for the prediction of diseases and also several studies
have conducted to evaluate their roles in pre‐eclampsia. Researchers
could successfully identify several circRNAs, which are differently
expressed during pre‐eclampsia. These data revealed that circRNAs
could be promising biomarkers in the prediction and diagnosis of
TABLE 1 Experimental studies that investigated the role of circRNAs in pre‐eclampsia
CircRNA Week of gestation Upregulated/downregulated in pre‐eclampsia
Publication
year Ref
circ_101222 Between 8 and 20 weeks Upregulated 2016 Zhang et al. (2016)
hsa_circRNA_100782 Between 30 and 34 weeks Upregulated 2016 Qian et al. (2016)
hsa_circRNA_104820 Between 30 and 34 weeks Upregulated 2016 Qian et al. (2016)
hsa_circRNA_102682 Between 30 and 34 weeks Upregulated 2016 Qian et al. (2016)
hg38_circ_0014736 Before 20 weeks Upregulated 2018 Bai et al. (2018)
hsa_circ_0015382 Before 20 weeks Upregulated 2018 Bai et al. (2018)
hsa_circ_0007121 Before 20 weeks Downregulated 2018 Bai et al. (2018)
circRNA_3286 Undergone cesarean section Downregulated 2018 Zhou et al. (2018)
circRNA_5593 Undergone cesarean section Downregulated 2018 Zhou et al. (2018)
circRNA_3800 Undergone cesarean section Downregulated 2018 Zhou et al. (2018)
hsa_circ_0036877 24 weeks Downregulated 2018 Hu et al. (2018)
hsa_circ_0004904 Before 20 weeks Upregulated 2018 Jiang et al. (2018)
hsa_circ_0001855 Before 20 weeks Upregulated 2018 Jiang et al. (2018)
Abbreviation: circRNA, circular RNA.
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pre‐eclampsia. However, further studies are necessary to elucidate
certain mechanisms of action for circRNAs in pre‐eclampsia.
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